TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) Return on equity 2016–2025
TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
17.8%FY2025 · since FY2016: 1.0% → 17.8%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 17.8% | +48.3 pp |
| FY2024 | -30.5% | -23.1 pp |
| FY2023 | -7.4% | +23.9 pp |
| FY2022 | -31.3% | -35.4 pp |
| FY2021 | 4.1% | +43.9 pp |
| FY2020 | -39.8% | -32.6 pp |
| FY2019 | -7.2% | +7.5 pp |
| FY2018 | -14.6% | +79.1 pp |
| FY2017 | -93.7% | -94.7 pp |
| FY2016 | 1.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TEVA financial trends
TEVA RevenueTEVA Net incomeTEVA Net marginTEVA Gross profitTEVA Gross marginTEVA Operating incomeTEVA Operating marginTEVA Operating cash flowTEVA Free cash flowTEVA Capital expendituresTEVA Stock buybacksTEVA Dividends paidTEVA Total assetsTEVA Total liabilitiesTEVA Shareholders’ equityTEVA overview →